应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
09887 维立志博-B
交易中 09-25 13:30:59
51.900
-0.650
-1.24%
最高
54.500
最低
50.800
成交量
12.81万
今开
52.300
昨收
52.550
日振幅
7.04%
总市值
103.28亿
流通市值
102.76亿
总股本
1.99亿
成交额
664.66万
换手率
0.06%
流通股本
1.98亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
异动解读｜维立志博-B盘中下跌5.6%，生物科技板块整体走弱叠加近期剧烈波动后获利回吐延续
行情直击 · 09-24 09:48
异动解读｜维立志博-B盘中下跌5.6%，生物科技板块整体走弱叠加近期剧烈波动后获利回吐延续
异动解读｜维立志博-B盘中上涨5.54%，ESMO突破性摘要入选叠加前日超跌反弹
行情直击 · 09-23 13:11
异动解读｜维立志博-B盘中上涨5.54%，ESMO突破性摘要入选叠加前日超跌反弹
异动解读｜维立志博-B盘中下跌5.59%，股份激励平台减持叠加获利回吐压力
行情直击 · 09-22
异动解读｜维立志博-B盘中下跌5.59%，股份激励平台减持叠加获利回吐压力
维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4–1BB双抗)单药治疗晚期EP-NEC的关键注册性IIB期研究入选LBA，以及三项研究获优选口头报告展示资格
智通财经 · 09-21
维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4–1BB双抗)单药治疗晚期EP-NEC的关键注册性IIB期研究入选LBA，以及三项研究获优选口头报告展示资格
维立志博-B三项研究获ESMO 2026优选口头报告 关键IIb期数据被列为突破性摘要
公告速递 · 09-21
维立志博-B三项研究获ESMO 2026优选口头报告 关键IIb期数据被列为突破性摘要
维立志博-B：Xiaoqiang Kang减持，好仓比例降至14.93%
港股披露 · 09-21
维立志博-B：Xiaoqiang Kang减持，好仓比例降至14.93%
维立志博-B：南京礼至企业管理谘询中心（有限合伙）减持，好仓比例降至14.93%
港股披露 · 09-21
维立志博-B：南京礼至企业管理谘询中心（有限合伙）减持，好仓比例降至14.93%
异动解读｜维立志博-B盘中上涨5.29%，大摩上调评级叠加WCLC数据催化延续反弹
行情直击 · 09-21
异动解读｜维立志博-B盘中上涨5.29%，大摩上调评级叠加WCLC数据催化延续反弹
大行评级丨大摩：上调维立志博目标价至93港元，评级升至“增持”
格隆汇 · 09-17
大行评级丨大摩：上调维立志博目标价至93港元，评级升至“增持”
港股异动 | 维立志博-B(09887.HK)午前涨超6% PD-L1/4-1BB双抗于WCLC更新重点数据 LBL-024国内即将上市
智通财经 · 09-17
港股异动 | 维立志博-B(09887.HK)午前涨超6% PD-L1/4-1BB双抗于WCLC更新重点数据 LBL-024国内即将上市
异动解读｜维立志博-B盘中上涨5.55%，WCLC数据发布后连续回调两日迎来反弹
行情直击 · 09-17
异动解读｜维立志博-B盘中上涨5.55%，WCLC数据发布后连续回调两日迎来反弹
异动解读｜维立志博-B盘中下跌6.04%，WCLC数据公布后股价延续回调态势
行情直击 · 09-16
异动解读｜维立志博-B盘中下跌6.04%，WCLC数据公布后股价延续回调态势
维立志博（09887）冲高回落跌超6% 于WCLC 2026公布维利信II期更新临床数据
金吾财讯 · 09-15
维立志博（09887）冲高回落跌超6% 于WCLC 2026公布维利信II期更新临床数据
异动解读｜维立志博-B盘中上涨6.18%，WCLC大会发布维利信II期临床积极数据提振市场信心
行情直击 · 09-15
异动解读｜维立志博-B盘中上涨6.18%，WCLC大会发布维利信II期临床积极数据提振市场信心
港股异动 | 维立志博-B(09887)高开近3% PD-L1/4-1BB双抗一线NSCLC缓解率与PFS率实现双重突破
智通财经 · 09-15
港股异动 | 维立志博-B(09887)高开近3% PD-L1/4-1BB双抗一线NSCLC缓解率与PFS率实现双重突破
维立志博-B(09887)：在WCLC 2026以口头报告形式发布维利信®(奥帕替苏米单抗，PD-L1/4-1BB双抗)联合化疗一线治疗NSCLC的II期临床研究更新资料
智通财经 · 09-14
维立志博-B(09887)：在WCLC 2026以口头报告形式发布维利信®(奥帕替苏米单抗，PD-L1/4-1BB双抗)联合化疗一线治疗NSCLC的II期临床研究更新资料
维立志博-B披露维利信联合化疗一线治疗NSCLC II期更新数据
公告速递 · 09-14
维立志博-B披露维利信联合化疗一线治疗NSCLC II期更新数据
异动解读｜维立志博-B盘中下跌5.07%，WCLC大会期间竞品数据亮眼加剧市场预期博弈
行情直击 · 09-14
异动解读｜维立志博-B盘中下跌5.07%，WCLC大会期间竞品数据亮眼加剧市场预期博弈
里昂：中国生物科技基本面仍稳固 首选百济神州(06160.HK)、信达生物(01801.HK)及维立志博(09887.HK)
智通财经 · 09-07
里昂：中国生物科技基本面仍稳固 首选百济神州(06160.HK)、信达生物(01801.HK)及维立志博(09887.HK)
异动解读｜维立志博-B盘中下跌5.32%，股东大额减持叠加中期亏损扩大持续承压
行情直击 · 09-04
异动解读｜维立志博-B盘中下跌5.32%，股东大额减持叠加中期亏损扩大持续承压
加载更多
公司概况
公司名称：
维立志博-B
所属市场：
SEHK
上市日期：
--
主营业务：
南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。
发行价格：
--
{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":51.9,"timestamp":1790314180744,"preClose":52.55,"halted":0,"volume":128106,"delay":0,"changeRate":-0.012369172216936225,"floatShares":198000000,"shares":199000000,"eps":-1.4125034315609484,"marketStatus":"交易中","change":-0.65,"latestTime":"09-25 13:30:59","open":52.3,"high":54.5,"low":50.8,"amount":6646625,"amplitude":0.070409,"askPrice":52,"askSize":1000,"bidPrice":51.9,"bidSize":1800,"shortable":3,"etf":0,"ttmEps":-1.6075129549073282,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790323800000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":52.55,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0.126786,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887","defaultTab":"news","newsList":[{"id":"1105244384","title":"异动解读｜维立志博-B盘中下跌5.6%，生物科技板块整体走弱叠加近期剧烈波动后获利回吐延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1105244384","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105244384?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:48","pubTimestamp":1790214488,"startTime":"0","endTime":"0","summary":"9月24日，维立志博-B盘中下跌5.6%，报53.05港元/股，成交额2373.68万港元。消息面上，生物科技板块整体承压，康方生物跌3.13%、荣昌生物跌4.57%、云顶新耀跌4.28%，板块情绪低迷。个股层面，公司近日围绕ESMO突破性摘要入选及股份激励平台南京礼至以均价63.69港元减持约85.91万股等事件剧烈波动，9月22日跌5.59%、23日涨5.54%，短期获利回吐压力再度释放。此外，公司中期净亏损约2.22亿元，同比扩大33.38%，基本面仍处亏损阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技板块走弱，维立志博承压下挫","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150006290","title":"异动解读｜维立志博-B盘中上涨5.54%，ESMO突破性摘要入选叠加前日超跌反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1150006290","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150006290?lang=zh_cn&edition=full","pubTime":"2026-09-23 13:11","pubTimestamp":1790140312,"startTime":"0","endTime":"0","summary":"9月23日，维立志博-B盘中上涨5.54%，报57.15港元/股，成交额6776.29万港元。消息面上，公司此前公告核心产品维利信单药治疗晚期肺外神经内分泌癌的关键注册性IIb期研究入选ESMO最新突破摘要，并获优选口头报告展示资格，将于10月26日进行展示，标志着该研究具备重大临床价值。前一交易日股价曾因股份激励平台南京礼至以均价63.69港元减持约85.91万股引发获利回吐，单日下跌5.59%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博ESMO摘要入选，股价强势反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186271672","title":"异动解读｜维立志博-B盘中下跌5.59%，股份激励平台减持叠加获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1186271672","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186271672?lang=zh_cn&edition=full","pubTime":"2026-09-22 09:40","pubTimestamp":1790041233,"startTime":"0","endTime":"0","summary":"9月22日，维立志博-B盘中下跌5.59%，报53.9港元/股，成交额1859.45万港元。消息面上，公司股份激励平台南京礼至于9月15日以均价63.69港元场内减持约85.91万股，涉资约5471.64万港元，减持后好仓比例由15.37%降至14.93%。尽管公司同日晚间公告维利信单药治疗晚期EP-NEC的关键注册性IIb期研究入选ESMO 2026最新突破摘要并获优选口头报告资格，但此前股价已因大摩上调评级至\"增持\"及WCLC数据催化连续反弹，短期获利回吐压力显现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"维立志博盘中走低，激励平台减持引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669016976","title":"维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4–1BB双抗)单药治疗晚期EP-NEC的关键注册性IIB期研究入选LBA，以及三项研究获优选口头报告展示资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2669016976","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669016976?lang=zh_cn&edition=full","pubTime":"2026-09-21 22:18","pubTimestamp":1790000312,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，在欧洲肿瘤内科学会年会2026年周年大会(2026 ESMO)， 本公司自主研发的在研药物维利信(奥帕替苏米单抗，PD-L1/4–1BB双抗)单药治疗晚期肺外神经内分泌癌(“EP-NEC)的关键注册性IIB期临床研究，已入选最新突破摘要(LBA)，并获优选口头报告展示资格，标志着有关研究具备突破性创新性质与重大临床价值，其研究结果有望改变现有临","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","09887","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199959551","title":"维立志博-B三项研究获ESMO 2026优选口头报告 关键IIb期数据被列为突破性摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=1199959551","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199959551?lang=zh_cn&edition=full","pubTime":"2026-09-21 22:15","pubTimestamp":1790000143,"startTime":"0","endTime":"0","summary":"2026年9月21日，南京维立志博生物科技股份有限公司发布自愿公告称，旗下在研双特异性抗体维利信单药用于晚期肺外神经内分泌癌的关键注册性IIb期研究入选2026年欧洲肿瘤内科学会年会“最新突破摘要”，并获得优选口头报告展示资格。官方日程显示，该口头报告将于2026年10月26日当地时间上午10时15分至10时25分进行展示。2026年7月，其创新生物制品上市申请被NMPA纳入优先审评审批程序，并于8月正式受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103284956","title":"维立志博-B：Xiaoqiang Kang减持，好仓比例降至14.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103284956","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103284956?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:41","pubTimestamp":1789983713,"startTime":"0","endTime":"0","summary":"Xiaoqiang Kang于2026年9月15日在联交所场内以每股均价63.6904港元卖出维立志博-B股份85.91万股，涉资约5471.64万港元，属场内主动交易，即在二级市场直接买卖股份。此次减持源于礼至合伙根据员工指示出售股份，Kang Xiaoqiang本人并未减持个人持股。Xiaoqiang Kang此次减持前持有维立志博-B好仓3037.59万股，占比15.37%；减持后持股量为2951.68万股，好仓比例降至14.93%。本次涉及关联方：Lai Shoupeng。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199500707","title":"维立志博-B：南京礼至企业管理谘询中心（有限合伙）减持，好仓比例降至14.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199500707","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199500707?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:21","pubTimestamp":1789982475,"startTime":"0","endTime":"0","summary":"维立志博-B的股份激励平台之一南京礼至企业管理谘询中心于2026年9月15日在联交所场内以每股均价63.6904港元卖出85.91万股股份，涉资约5471.64万港元。该笔交易属场内主动交易，即在二级市场直接买卖股份，系根据公司员工指示出售其各自归属的股份。礼至合伙此次减持前持有维立志博-B好仓3037.59万股，占比15.37%；减持后持股量为2951.68万股，好仓比例降至14.93%。本次涉及关联方：Kang Xiaoqiang、Lai Shoupeng、LeadsTech Limited、引领生物有限公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191469692","title":"异动解读｜维立志博-B盘中上涨5.29%，大摩上调评级叠加WCLC数据催化延续反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1191469692","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191469692?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:45","pubTimestamp":1789955112,"startTime":"0","endTime":"0","summary":"9月21日，维立志博-B盘中上涨5.29%，报58.7港元/股，成交额2229.34万港元。此前里昂亦维持116.9港元目标价及\"跑赢大市\"评级。公司于9月14日在WCLC以口头报告形式发布维利信联合化疗一线治疗NSCLC的II期更新数据，整体ORR达71.0%，非鳞状PD-L1阳性亚组ORR达81.8%、DCR达100%，安全性良好。公司正积极推进维利信一线NSCLC的III期临床布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B获大摩上调评级，盘中上涨引关注","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668950248","title":"大行评级丨大摩：上调维立志博目标价至93港元，评级升至“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2668950248","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668950248?lang=zh_cn&edition=full","pubTime":"2026-09-17 16:55","pubTimestamp":1789635304,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","09887","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668953934","title":"港股异动 | 维立志博-B(09887.HK)午前涨超6% PD-L1/4-1BB双抗于WCLC更新重点数据 LBL-024国内即将上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2668953934","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668953934?lang=zh_cn&edition=full","pubTime":"2026-09-17 11:35","pubTimestamp":1789616154,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000500386.USD","BK1161","HK0000252160.HKD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144405437","title":"异动解读｜维立志博-B盘中上涨5.55%，WCLC数据发布后连续回调两日迎来反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1144405437","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144405437?lang=zh_cn&edition=full","pubTime":"2026-09-17 10:05","pubTimestamp":1789610758,"startTime":"0","endTime":"0","summary":"消息面上，公司于9月14日在WCLC世界肺癌大会以口头报告形式发布核心产品维利信联合化疗一线治疗NSCLC的II期临床更新数据，整体ORR达71.0%，非鳞状NSCLC PD-L1阳性亚组ORR达81.8%、DCR达100%，安全性良好。数据发布后股价经历两个交易日连续回调，从高点65.75港元累计下跌超18%，呈典型\"利好兑现\"走势，今日出现技术性反弹。此外，里昂此前将公司目标价上调至116.9港元并维持\"跑赢大市\"评级，公司正积极推进维利信一线治疗NSCLC的III期临床布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"WCLC数据亮眼，维立志博-B反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164373426","title":"异动解读｜维立志博-B盘中下跌6.04%，WCLC数据公布后股价延续回调态势","url":"https://stock-news.laohu8.com/highlight/detail?id=1164373426","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164373426?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:07","pubTimestamp":1789524473,"startTime":"0","endTime":"0","summary":"9月16日，维立志博-B盘中下跌6.04%，报53.65港元/股，成交额4594.73万港元，延续前一交易日冲高回落走势。消息面上，公司于9月14日在WCLC世界肺癌大会以口头报告形式发布核心产品维利信联合化疗一线治疗NSCLC的II期临床更新数据，非鳞状NSCLC PD-L1阳性亚组ORR达81.8%、DCR达100%。然而前一交易日股价在高开至65.75港元后即大幅回落跌超6%，呈现典型的\"利好兑现\"走势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"维立志博WCLC数据落地，股价延续回调","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667618110","title":"维立志博（09887）冲高回落跌超6% 于WCLC 2026公布维利信II期更新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2667618110","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667618110?lang=zh_cn&edition=full","pubTime":"2026-09-15 10:52","pubTimestamp":1789440763,"startTime":"0","endTime":"0","summary":"金吾财讯 | 维立志博-B 港股早盘高开低走，最高涨到65.75港元，最新跌6.42%，报57.6港元，成交额2.63亿港元。消息面上，维立志博-B发布公告，在2026年世界肺癌大会以口头报告形式发布自主研发的在研药物维利信联合化疗一线治疗非小细胞肺癌患者的II期临床研究更新资料。根据更新资料，展现出前所未有的高缓解率，在鳞状NSCLCPD-L1阴性和阳性患者中观察到几乎完全一致的临床获益，而非鳞状NSCLCPD-L1TPS≥1%患者可获得深度且持久的肿瘤缓解。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991622","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000500386.USD","BK1161","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105909890","title":"异动解读｜维立志博-B盘中上涨6.18%，WCLC大会发布维利信II期临床积极数据提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1105909890","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105909890?lang=zh_cn&edition=full","pubTime":"2026-09-15 09:31","pubTimestamp":1789435885,"startTime":"0","endTime":"0","summary":"9月15日，维立志博-B盘中上涨6.18%，报65.3港元/股，成交额1549.37万港元。消息面上，公司于9月14日晚间公告，在WCLC 2026世界肺癌大会以口头报告形式发布核心产品维利信联合化疗一线治疗NSCLC的II期临床更新数据。此外，里昂此前将公司目标价上调至116.9港元，公司正积极推进维利信III期临床布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博盘中上涨，维利信II期数据超预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667697972","title":"港股异动 | 维立志博-B(09887)高开近3% PD-L1/4-1BB双抗一线NSCLC缓解率与PFS率实现双重突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2667697972","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667697972?lang=zh_cn&edition=full","pubTime":"2026-09-15 09:30","pubTimestamp":1789435810,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B高开近3%，截至发稿，涨2.44%，报63港元，成交额458.64万港元。消息面上，9月14日，维立志博-B发布公告，在2026年世界肺癌大会以口头报告形式发布自主研发的在研药物维利信联合化疗一线治疗非小细胞肺癌患者的II期临床研究更新资料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","09887","BK4585","LU1169590202.USD","PD","BK4023","VXUS","HK0000500386.USD","BK1161","HK0000252160.HKD","LU1169589451.USD","HK0000252152.HKD","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654690","title":"维立志博-B(09887)：在WCLC 2026以口头报告形式发布维利信®(奥帕替苏米单抗，PD-L1/4-1BB双抗)联合化疗一线治疗NSCLC的II期临床研究更新资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654690","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667654690?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:20","pubTimestamp":1789377635,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，在2026年世界肺癌大会以口头报告形式发布自主研发的在研药物维利信联合化疗一线治疗非小细胞肺癌患者的II期临床研究更新资料。非鳞状NSCLC PD-L1阳性亚组ORR达81.8%，DCR达100.0%，6个月PFS率达90.0%。维利信联合化疗整体安全性良好，安全性特征与PD-L1单抗联合化疗相似，未观察到新的安全信号。目前，本公司正在积极推进维利信一线治疗NSCLC的III期临床研究布局，力争早日让这款创新疗法惠及更多患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","BK4023","BK1161","HK0000252160.HKD","LU1169590202.USD","HK0000500386.USD","LU1169589451.USD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144938818","title":"维立志博-B披露维利信联合化疗一线治疗NSCLC II期更新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1144938818","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144938818?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:16","pubTimestamp":1789377382,"startTime":"0","endTime":"0","summary":"2026年9月14日，南京维立志博生物科技股份有限公司发布自愿公告，公布其自主研发的PD-L1/4-1BB双特异性抗体维利信联合化疗用于非小细胞肺癌一线治疗的II期临床研究最新结果。该结果于2026年世界肺癌大会以口头报告形式发布。截至2026年7月1日，研究共入组63例既往未接受系统治疗的NSCLC患者，其中非鳞状31例、鳞状32例，IV期患者比例超过90%。公司提醒投资者，无法保证维利信能够成功开发或最终获批上市。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194772445","title":"异动解读｜维立志博-B盘中下跌5.07%，WCLC大会期间竞品数据亮眼加剧市场预期博弈","url":"https://stock-news.laohu8.com/highlight/detail?id=1194772445","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194772445?lang=zh_cn&edition=full","pubTime":"2026-09-14 09:47","pubTimestamp":1789350479,"startTime":"0","endTime":"0","summary":"9月14日，维立志博-B盘中下跌5.07%，报57.15港元/股，成交额1761.26万港元。消息面上，WCLC世界肺癌大会正在首尔召开，竞争对手康方生物于9月13日发布核心产品依沃西头对头K药的HARMONi-2研究OS显著阳性结果，当日康方生物开盘上涨3.65%。维立志博核心产品LBL-024联合化疗一线NSCLC的II期更成熟数据定于9月14日更新，市场对数据能否达到与PD-1×VEGF双抗相当的PFS水平存在不确定性预期，叠加此前股价已从8月底70港元以上回落，短期博弈压力加大。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"WCLC竞品数据亮眼，维立志博承压下跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665395840","title":"里昂：中国生物科技基本面仍稳固 首选百济神州(06160.HK)、信达生物(01801.HK)及维立志博(09887.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665395840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665395840?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:52","pubTimestamp":1788745948,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0228659784.USD","03069","HK0000165453.HKD","HK0000252160.HKD","LU0307460666.USD","LU0588546209.SGD","LU1969619763.USD","LU2097828631.EUR","HK0000500386.USD","LU0502904849.HKD","LU1770034418.SGD","KURE","LU1251922891.USD","LU2097828714.EUR","BK1588","LU2488822045.USD","LU2097828474.EUR","LU1188198961.HKD","BK1500","LU0463099449.HKD","BK1589","LU2097828805.USD","LU2097828557.USD","09887","LU0455707207.USD","06160","LU0828237510.HKD","LU1303224171.USD","BK1583","LU0326950275.SGD","01801","LU2242644610.SGD","HK0000252152.HKD","LU0244354667.USD","LU2328871848.SGD","LU1719994722.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175698768","title":"异动解读｜维立志博-B盘中下跌5.32%，股东大额减持叠加中期亏损扩大持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1175698768","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175698768?lang=zh_cn&edition=full","pubTime":"2026-09-04 14:05","pubTimestamp":1788501948,"startTime":"0","endTime":"0","summary":"9月4日，维立志博-B盘中下跌5.32%，报64.1港元，成交额1.95亿港元。此外，公司此前披露中期业绩，上半年净亏损约2.22亿元，同比扩大33.38%，研发成本同比增长44.92%至1.91亿元，尚无产品销售收入，亏损持续扩大对市场情绪形成压制。维立志博-B是一家专注于抗体新药研发及商业化的生物科技公司，核心产品LBL-024的NDA已获国家药监局受理，多项临床管线正在推进中。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"维立志博-B承压下跌，股东大额减持叠加亏损扩大","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.0574},{"period":"1month","weight":-0.2956},{"period":"3month","weight":0.0599},{"period":"6month","weight":-0.2946},{"period":"1year","weight":-0.1632},{"period":"ytd","weight":0.0304}],"compareEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0922},{"period":"6month","weight":-0.0076},{"period":"1year","weight":-0.0663},{"period":"ytd","weight":-0.0339}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}